This randomized, single-center, open-label, one-sequence, two-period crossover study in three
parts will assess the effects of multiple doses of ketoconazole, rifampicin and
ritonavir-boosted atazanavir on the pharmacokinetics of a single dose of RO5093151 in healthy
male and female volunteers. In Period 1, subjects will receive a single oral dose of
RO5093151. In Period 2, subjects will receive a single oral dose of RO5093151 and multiple
oral doses of either ketoconazole, rifampicin or ritonavir-boosted atazanavir. Anticipated
time on study is up to 8.5 weeks.